GILEAD SCIENCES, INC. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
GILEAD SCIENCES, INC. (GILD) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $211.08 million as of 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-05-08
- 2013-03-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $211.08M.
- 2012-12-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $205.06M.
- 2012-09-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $199.71M.
- 2012-06-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $140.90M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $211.08M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $205.06M 10-Q · filed 2013-05-08 |
| 2012-09-30 | $199.71M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $140.90M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $138.33M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $135.59M 10-K · filed 2013-02-27 |
| 2011-03-31 | $11.10M 10-Q · filed 2012-05-04 |
| 2010-12-31 | $11.10M 10-Q · filed 2012-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |